Hypogonadism Trial Designs: FDA Panel Favors Symptom Assessments, Fertility Measures
Executive Summary
US advisory committee rejects Repros Therapeutics' proposal for an obesity-related hypogonadism study in which efficacy is based upon testosterone levels and sperm concentrations.